// App-Quantinova.ai

3048 : Drug repurposing: Validation of sulfasalazine as a radiosensitizer in melanoma by blocking system Xc

Researchers

Presenter

  • Hilde Elise Frde

Principal Investigators

  • Linda Sleire

  • Heidi Espedal

  • Jan Ingemann Heggdal

  • Frode Selheim

  • Paal-Henning Pedersen

  • Per yvind Enger

Medical Centers

  • Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway

  • Department of Biomedicine, Molecular Imaging Center (MIC), University of Bergen, Bergen, Norway

  • Department of Oncology, Haukeland University Hospital, Bergen, Norway

  • Department of Biomedicine, Proteomics Unit (Probe), University of Bergen, Bergen, Norway

  • Department of Clinical Medicine, K , University of Bergen, Bergen, Norway Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway

  • Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.

Locations

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Sulfasalazine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved